Treatment of Pseudomonas aeruginosa UTI in Parkinson's Disease Patients

Initial Assessment and Management

Hyaline casts in urine with Pseudomonas aeruginosa suggest a biofilm infection, especially if the patient has an indwelling urinary catheter, which is common in Parkinson's disease patients with urinary dysfunction, and removal or replacement of the catheter is necessary as antibiotic therapy alone is insufficient to clear biofilm present on catheters 1
If a urinary catheter is present, it must be removed or replaced as antibiotic therapy alone is insufficient to clear biofilm present on catheters and will only temporarily suppress symptoms, according to the Clinical Microbiology and Infection guidelines 1

For resistant P. aeruginosa, first-line options include Ceftolozane-tazobactam or ceftazidime-avibactam based on susceptibility testing, as recommended by the International Journal of Antimicrobial Agents 2
Alternative options for resistant P. aeruginosa include Imipenem-cilastatin-relebactam, cefiderocol, or colistin-based therapy, according to the International Journal of Antimicrobial Agents 2

For patients with neurological deterioration or sepsis, consider extending treatment to 14 days, as suggested by the Critical Care Medicine guidelines 3
Monitor for clinical improvement within 48-72 hours; if no improvement is seen, reassess therapy and consider changing antibiotics, according to the Clinical Microbiology and Infection guidelines 1
Assess renal function before and during treatment, especially in elderly Parkinson's patients who may have reduced clearance, as recommended by the International Journal of Antimicrobial Agents 2

For severe infections or sepsis due to P. aeruginosa, consider combination therapy with two antibiotics to which the isolate is susceptible, as suggested by the Clinical Infectious Diseases guidelines 4
Monotherapy is appropriate for non-severe infections with susceptible strains, according to the Clinical Infectious Diseases and European Respiratory Journal guidelines 4, 5
Combination therapy may delay development of resistance compared to monotherapy, as recommended by the European Respiratory Journal 6

Prophylactic antibiotics are generally not recommended due to concerns about developing resistant strains, as stated by the Clinical Microbiology and Infection guidelines 7